Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Shattuck Labs, Inc. - Common Stock
(NQ:
STTK
)
1.010
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
20
Open
1.010
Bid (Size)
1.010 (20)
Ask (Size)
1.070 (18)
Prev. Close
1.010
Today's Range
1.010 - 1.010
52wk Range
0.9900 - 11.76
Shares Outstanding
42,122,778
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
October 29, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Performance
YTD
-86.64%
-86.64%
1 Month
-21.09%
-21.09%
3 Month
-69.11%
-69.11%
6 Month
-86.52%
-86.52%
1 Year
-56.65%
-56.65%
More News
Read More
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
October 28, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Shattuck Labs Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
August 27, 2024
Via
Benzinga
Assessing Shattuck Labs: Insights From 7 Financial Analysts
August 02, 2024
Via
Benzinga
Assessing Shattuck Labs: Insights From 6 Financial Analysts
June 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 08, 2024
Via
Benzinga
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
October 04, 2024
Via
NewMediaWire
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
October 04, 2024
Via
TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
October 03, 2024
Via
NewMediaWire
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
October 03, 2024
Via
TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
October 02, 2024
Via
NewMediaWire
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
October 02, 2024
Via
TheNewswire.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 01, 2024
Via
Benzinga
Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline
October 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 01, 2024
Via
Benzinga
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
October 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
STTK Stock Earnings: Shattuck Labs Misses EPS, Beats Revenue for Q2 2024
August 01, 2024
Via
InvestorPlace
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
July 30, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
July 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
June 20, 2024
Via
Benzinga
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
June 14, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.